LLY.SW stock opened on SIX at CHF760.00, down CHF140.00 or 15.56% from the previous close of CHF900.00 on 06 Mar 2026. The sharp intraday gap reflects a Swiss-listed repricing and near-zero reported local volume, which amplified the move. Investors should note the company’s trailing PE 45.20 and EPS CHF17.70, and watch short-term technical levels and analyst commentary for clues on whether this is a temporary gap or start of a longer correction.

LLY.SW stock intraday move and immediate drivers

The most important fact is the intraday gap: open CHF760.00, previous close CHF900.00, a CHF140.00 decline or 15.56%. One key driver is the Swiss listing’s thin local trading (reported volume 0, avgVolume 1), which magnified the move versus US-listed liquidity. Institutional holdings and ETF rebalances can accentuate moves in ADR cross-lists, as recent funds data show high Eli Lilly weights in healthcare funds Bloomberg.

Valuation snapshot: PE, EPS and balance sheet specifics

Eli Lilly trades at PE 45.20 with EPS CHF17.70, implying market expectations of continued high growth. Key ratios include price-to-sales 12.10 and price-to-book 34.62, while dividend yield is modest at 0.61%. The balance sheet shows cash per share CHF8.10 and elevated interest coverage at 36.78, underlining strong cash generation despite a high valuation.

Technical read: support, momentum and moving averages

On technicals, RSI is 41.88 and MACD histogram at -5.35, signalling negative momentum but not extreme capitulation. The 50-day average sits at CHF829.90 and the 200-day at CHF707.40; the intraday price at CHF760.00 is below the 50-day and above the 200-day, so near-term support is around CHF755.82 (Bollinger lower). Traders should watch CHF707.40 as the next structural support.

Operational and cash flow metrics that matter

Eli Lilly’s cash flow profile remains robust: operating cash flow per share CHF18.75 and free cash flow per share CHF9.53. Net income per share is CHF23.01 and return on invested capital is 29.74%, supporting long-term earnings power. High margins (gross margin 83.04%, net margin 31.66%) explain elevated multiples but also raise sensitivity to revenue growth shifts and pricing pressures.

Sector context and market drivers for LLY.SW

Healthcare is holding better than broader markets, but LLY.SW’s 15.56% drop far outpaced sector moves today. The stock’s market cap on SIX is about CHF616,403,227,200.00, making it one of the largest healthcare names on local screens and a common weight in global funds. Sector flow, regulatory headlines and product news will drive re-rating; for fund holdings context see MarketWatch ETF overview.

Meyka grade, analyst consensus and risks

Meyka AI rates LLY.SW with a score out of 100: 76.82 / B+ (BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Key downside risks are valuation compression (high P/B and P/S), regulatory setbacks and dependence on a handful of blockbusters. Ratings from other models show mixed signals, so position sizing and risk controls are essential.

Final Thoughts

Intraday, LLY.SW stock shows a pronounced repricing: CHF760.00 vs previous close CHF900.00. The move appears driven by low local liquidity on SIX and ETF/fund flows rather than a single public company shock. Short-term traders should monitor support at CHF755.82 and structural support at the 200-day average CHF707.40. Meyka AI’s forecast model projects a yearly target CHF986.02, implying an implied upside of 29.74% from the current price CHF760.00, while the quarterly projection is CHF730.38 (implied downside -3.87%). Forecasts are model-based projections and not guarantees. Use the Meyka AI-powered market analysis platform and the stock’s financial ratios—PE 45.20, EPS CHF17.70, free cash flow per share CHF9.53—to size any position, and watch official earnings and regulatory updates ahead of the next reporting date on 2026-04-30. For a deeper tracker, see our internal page at Meyka LLY.SW stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.